The obesity treatment landscape is evolving rapidly, with GLP-1 drugs paving the way for more effective care. Experts envision a future where various treatment modalities work together for better outcomes.
New Delhi, India Jun 20, 2026 ALN: The popularity of GLP-1 medications such as semaglutide (Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro and Zepbound) has dramatically reshaped the way obesity is treated. However, specialists say these drugs are only one piece of the puzzle when it comes to managing one of the most widespread chronic conditions in the United States. Obesity, defined as an excessive accumulation of body fat, is a complex disease that has reached epidemic proportions, affecting millions of individuals and posing significant risks, including diabetes, cardiovascular diseases, and certain cancers.
A new commentary in the American Gastroenterological Association journal Gastroenterology revisits the influential POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework, originally introduced in 2017. Titled "Revisiting POWER in the GLP-1 Age," the update reflects major developments in obesity care. These developments range from the arrival of highly effective weight loss medications to advances in endoscopic therapies, broader use of bariatric surgery, and the growing role of precision medicine. This commentary not only highlights the importance of these medications but also emphasizes the need for a more holistic approach to obesity management.
According to the authors, GLP-1 receptor agonists have significantly changed the obesity treatment landscape. These medications work by mimicking the action of the glucagon-like peptide-1 hormone, which helps regulate appetite and insulin secretion. As a result, patients using these medications often experience substantial weight loss, which can lead to improvements in obesity-related conditions. At the same time, the authors emphasize that obesity care is becoming increasingly comprehensive, combining medications with endoscopic procedures and surgical options when appropriate. This shift acknowledges that obesity is not merely a matter of willpower or lifestyle but is influenced by a variety of biological, environmental, and psychological factors.
The updated framework also incorporates the emerging concept of clinical obesity. This approach recognizes obesity as a chronic disease that affects multiple body systems and highlights the limitations of relying solely on body mass index (BMI) to evaluate risks. BMI, while commonly used, does not account for variations in body composition, fat distribution, and other indicators. By viewing obesity through a clinical lens, care providers can better identify the most effective interventions tailored to individual patients.
Researchers note that obesity treatment is increasingly moving toward a multidisciplinary model that brings together different therapeutic approaches. Rather than viewing medications, procedures, and surgery as separate strategies, experts see them as complementary tools that can be tailored to individual patients. This integrated approach allows for a more personalized treatment plan, which can address the unique challenges faced by each patient. For instance, a patient with a high BMI but few comorbidities may benefit from lifestyle interventions and medication, while another with severe obesity and multiple issues might require surgical intervention.
The commentary highlights growing evidence for endoscopic bariatric and metabolic therapies, including endoscopic sleeve gastroplasty, as effective treatment options for obesity. These minimally invasive procedures can provide significant weight loss and improvement in metabolic , often with shorter recovery times compared to traditional bariatric surgery. Endoscopic therapies represent an exciting frontier in obesity treatment, as they can be more accessible to patients who may not qualify for or prefer to avoid surgical options.
The authors also point to advances in genetics and precision medicine that could help physicians identify which treatments are most likely to benefit specific patients. As researchers learn more about the biological factors that influence obesity, treatment plans may become increasingly personalized. For example, genetic testing could determine how a patient metabolizes certain medications, guiding the choice of treatment to maximize efficacy and minimize side effects. This level of customization could revolutionize obesity management, making it more effective and sustainable in the long term.
Another promising area involves combining therapies. Evidence suggests that pairing GLP-1 medications with endoscopic procedures or bariatric surgery could lead to greater weight loss and longer-lasting results than either approach alone. This combinatorial strategy leverages the strengths of different treatment modalities, potentially enhancing patient outcomes. For instance, a patient undergoing bariatric surgery might benefit from GLP-1 therapy post-operatively to further control appetite and support weight maintenance, illustrating the potential for synergistic effects in obesity management.
The paper also underscores the important role gastroenterologists and hepatologists play in treating obesity and its related complications. These specialists frequently care for patients with obesity-associated conditions, including metabolic dysfunction-associated steatotic liver disease (MASLD), gastroesophageal reflux disease (GERD), gallbladder disease, and a range of gastrointestinal complications linked to obesity. Given their expertise in managing these interconnected issues, gastroenterologists are well positioned to take a leading role in the evolving landscape of obesity treatment.
As the understanding of obesity as a chronic disease deepens, the involvement of gastroenterologists and hepatologists in obesity management will likely expand. These specialists can help implement comprehensive treatment strategies that address not only weight loss but also the myriad complications associated with obesity. This holistic approach is crucial, as simply focusing on weight can overlook the complex interplay of factors that contribute to obesity and its related issues.
Furthermore, as new treatments and technologies emerge, gastroenterologists will need to stay abreast of advancements in obesity care. This includes understanding the implications of new medications, surgical techniques, and endoscopic procedures, as well as the ongoing research into the biological underpinnings of obesity. By remaining informed and adaptable, these specialists can ensure that they provide the best possible care for their patients, ultimately leading to improved outcomes and quality of life.
In conclusion, while GLP-1 medications have undeniably changed the landscape of obesity treatment, experts suggest that the real revolution lies in the comprehensive, multidisciplinary approach to obesity management. By integrating medications, endoscopic therapies, and surgical options, and recognizing obesity as a complex chronic disease, care providers can develop personalized treatment plans that address the unique needs of each patient. As the field of obesity care continues to evolve, the collaboration between various specialties, including gastroenterology, will be essential in shaping the future of obesity treatment and improving the lives of those affected by this condition.
To learn more about the latest developments in Health News, stay updated with our exclusive reports and analyses on AiLensNews.
